Lead Sponsor

Aristotle University Of Thessaloniki

Age

29 - 80 years

Sex

ALL

Healthy Volunteers

No

•Consecutive primary open-angle (POAG) and exfoliative glaucoma (XFG) patients will be recruited.
•Patients included will be older than 29 years
•Have early to moderate POAG, or XFG (less than 12 mean deviation visual field loss attributed to glaucoma and 0.8 or better vertical cup-to-disc ratio)
•Will be on therapy with latanoprost for more than 3 months;
•Have at treated baseline IOP at 10:00 (two consecutive readings) greater than 21 mm Hg
•Have a reliable visual field (at least two visual fields with less than 30% fixation losses, false positives or negatives)
•Have a best corrected distance Snellen visual acuity \> 1/10
•Have corneal pachymetry within the 550 ± 55 μm range, understand the study instructions and are willing to attend all follow-up appointments
•Are willing to comply with study medication usage
•And have open, normal appearing angles

•Patients will be excluded if they have: a risk for significant deterioration during the study
•Known previous history of lack of adequate response (\< 10% reduction) to any topical glaucoma medication
•Less than 20% daytime IOP reduction on latanoprost;
•Systemic contraindications to topical beta-blockers (asthma, bradycardia, severe congestive heart disease)
•Known contraindications to prostaglandins, history of ocular herpetic disease, or cystoid macular edema
•History of trauma, inflammation, surgery or past use of steroids (within two months)
•Severe dry eyes
•Use of contact lenses
•Signs of ocular infection, except blepharitis
•Corneal abnormality that may affect IOP measurements
•Unwillingness to accept the risk for hyperchromia of the iris or development of hypertrichosis
•And females of childbearing potential or lactating mothers

Related studies

NCT07462000 · Primary Open-Angle Glaucoma (POAG), Cataract

NCT07217678 · Glaucoma, Open-Angle Glaucoma, and more

NCT07354477 · Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), and more

NCT06267274 · Open-angle Glaucoma, Ocular Hypertension

NCT05432245 · Primary Open-angle Glaucoma, Cataract

24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations